Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

Convertible bonds can be enticing for biotech companies since they offer less dilutive financing than equity offerings and often carry low interest rates.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...